An antimicrobial blue light device to manage infection at the skin-implant interface of percutaneous osseointegrated implants.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
03
2023
accepted:
05
08
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Antimicrobial blue light (aBL) is an attractive option for managing biofilm burden at the skin-implant interface of percutaneous osseointegrated (OI) implants. However, marketed aBL devices have both structural and optical limitations that prevent them from being used in an OI implant environment. They must be handheld, preventing even irradiation of the entire skin-implant interface, and the devices do not offer sufficient optical power outputs required to kill biofilms. We present the developmental process of a unique aBL device that overcomes these limitations. Four prototypes are detailed, each being a progressive improvement from the previous iteration as we move from proof-of-concept to in vivo application. Design features focused on a cooling system, LED orientation, modularity, and "sheep-proofing". The final prototype was tested in an in vivo OI implant sheep model, demonstrating that it was structurally and optically adequate to address biofilm burdens at the skin-implant of percutaneous OI implants. The device made it possible to test aBL in the unique OI implant environment and compare its efficacy to clinical antibiotics-data which had not before been achievable. It has provided insight into whether or not continued pursual of light therapy research for OI implants, and other percutaneous devices, is worthwhile. However, the device has drawbacks concerning the cooling system, complexity, and size if it is to be translated to human clinical trials. Overall, we successfully developed a device to test aBL therapy for patients with OI implants and helped progress understanding in the field of infection management strategies.
Identifiants
pubmed: 37624860
doi: 10.1371/journal.pone.0290347
pii: PONE-D-23-08311
pmc: PMC10456172
doi:
Substances chimiques
Anti-Infective Agents
0
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0290347Informations de copyright
Copyright: © 2023 Ong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Biomed Mater Res A. 2013 Jul;101(7):2075-82
pubmed: 23281016
J Mater Sci Mater Med. 2017 Oct 4;28(11):179
pubmed: 28980174
Appl Environ Microbiol. 2016 Jun 13;82(13):4006-4016
pubmed: 27129967
Br J Exp Pathol. 1957 Dec;38(6):573-86
pubmed: 13499821
J Bacteriol. 1943 Jul;46(1):39-56
pubmed: 16560677
Photomed Laser Surg. 2017 Mar;35(3):150-156
pubmed: 27759498
Br J Exp Pathol. 1948 Feb;29(1):20-39
pubmed: 18865102
J Am Acad Orthop Surg. 2019 Nov 15;27(22):e977-e985
pubmed: 31181031
Med Sci Monit. 2012 Jun;18(6):RA89-96
pubmed: 22648264
NPJ Biofilms Microbiomes. 2019 Oct 9;5(1):29
pubmed: 31602310
Drug Resist Updat. 2017 Nov;33-35:1-22
pubmed: 29145971
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32493838
J Photochem Photobiol B. 2021 Feb;215:112109
pubmed: 33486397
Biomed Eng Lett. 2019 Nov 11;10(1):5-16
pubmed: 32175127